Accepted for Publication: December 18, 2019.
Corresponding Author: Hooman Kamel, MD, Clinical and Translational Neuroscience Unit, Feil Family Brain and Mind Research Institute and Department of Neurology, Weill Cornell Medicine, 420 E 70th St, LH-413, New York, NY 10021 (hok9010@med.cornell.edu).
Published Online: February 24, 2020. doi:10.1001/jamaneurol.2020.0010
Author Contributions: Dr Kamel had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Kamel, Kleindorfer, Johnston.
Acquisition, analysis, or interpretation of data: Kamel, Zhang, Levitan, V. Howard, G. Howard, Soliman.
Drafting of the manuscript: Kamel.
Critical revision of the manuscript for important intellectual content: Zhang, Kleindorfer, Levitan, V. Howard, G. Howard, Soliman, Johnston.
Statistical analysis: Kamel, Zhang, Levitan.
Obtained funding: Kamel, Johnston.
Administrative, technical, or material support: Kamel, Johnston.
Supervision: Johnston.
Conflict of Interest Disclosures: Dr Kamel reported serving as coprincipal investigator for the National Institutes of Health (NIH)–funded ARCADIA trial, which receives an in-kind study drug from the BMS-Pfizer Alliance and in-kind study assays from Roche Diagnostics, a steering committee member of Medtronic's Stroke AF trial (uncompensated), an end point adjudication committee member for a trial of empagliflozin for Boehringer-Ingelheim, and an advisory board member for Roivant Sciences on the topic of Factor XI inhibition. Dr Levitan reported grants from Amgen and personal fees from Novartis outside the submitted work. Dr Johnston reported nonfinancial support from Sanofi and grants from the NIH/National Institute of Neurological Disorders and Stroke (NINDS) and AstraZeneca. No other disclosures were reported.
Funding/Support: The POINT trial was funded by NIH/NINDS (grants U01NS062835, U01NS056975, and U01NS059041). Dr Kamel is supported by the NIH (grants R01NS097443 and R01HL144541).
Role of the Funder/Sponsor: The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Dr Kamel is a Deputy Editor of JAMA Neurology, but he was not involved in any of the decisions regarding review of the manuscript or its acceptance.
3.Rosamond
WD , Folsom
AR , Chambless
LE ,
et al. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the Atherosclerosis Risk in Communities (ARIC) cohort.
Stroke. 1999;30(4):736-743. doi:
10.1161/01.STR.30.4.736
PubMedGoogle ScholarCrossref 4.Kleindorfer
DO , Khoury
J , Moomaw
CJ ,
et al. Stroke incidence is decreasing in whites but not in blacks: a population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/Northern Kentucky Stroke Study.
Stroke. 2010;41(7):1326-1331. doi:
10.1161/STROKEAHA.109.575043
PubMedGoogle ScholarCrossref 7.Kennedy
BS . Does race predict stroke readmission? An analysis using the truncated negative binomial model.
J Natl Med Assoc. 2005;97(5):699-713.
PubMedGoogle Scholar 9.Estol
CJ , Bath
PM , Gorelick
PB , Cotton
D , Martin
RH ; PRoFESS Publications Committee and PRoFESS Investigators. Differences in ischemic and hemorrhagic recurrence rates among race-ethnic groups in the PRoFESS secondary stroke prevention trial.
Int J Stroke. 2014;9(Suppl A100):43-47. doi:
10.1111/ijs.12269PubMedGoogle ScholarCrossref 11.Luengo-Fernandez
R , Gray
AM , Rothwell
PM . Effect of urgent treatment for transient ischaemic attack and minor stroke on disability and hospital costs (EXPRESS study): a prospective population-based sequential comparison.
Lancet Neurol. 2009;8(3):235-243. doi:
10.1016/S1474-4422(09)70019-5
PubMedGoogle ScholarCrossref 12.Johnston
SC , Easton
JD , Farrant
M ,
et al; Clinical Research Collaboration, Neurological Emergencies Treatment Trials Network, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.
N Engl J Med. 2018;379(3):215-225. doi:
10.1056/NEJMoa1800410
PubMedGoogle ScholarCrossref 16.Leira
EC , Adams
HP
Jr , Rosenthal
GE , Torner
JC . Baseline NIH stroke scale responses estimate the probability of each particular stroke subtype.
Cerebrovasc Dis. 2008;26(6):573-577. doi:
10.1159/000165109
PubMedGoogle ScholarCrossref 22.Kamel
H , O’Neal
WT , Okin
PM , Loehr
LR , Alonso
A , Soliman
EZ . Electrocardiographic left atrial abnormality and stroke subtype in the atherosclerosis risk in communities study.
Ann Neurol. 2015;78(5):670-678. doi:
10.1002/ana.24482
PubMedGoogle ScholarCrossref